Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (12,599,569)	$ (12,958,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	21,715	22,318
Stockbased compensation	478,141	489,436
Issuance of common stock to consultants	39,050	17,435
Foreign currency loss (gain)	95,319	(71,800)
Changes in operating assets and liabilities:
Prepaid expenses and other current and noncurrent assets	(217,906)	(96,674)
Accounts payable	(646,701)	(314,207)
Accrued expenses	(64,488)	(115,541)
Deferred grant revenue		(528,974)
Net cash used in operating activities	(12,894,439)	(13,556,718)
Cash flows from investing activities:
Purchases of property and equipment		(15,478)
Net cash used in investing activities		(15,478)
Cash flows from financing activities:
Proceeds from the exercise of warrants	91
Proceeds from issuance of common stock	5,047,606	16,140,356
Common stock issuance costs	(407,459)	(1,318,461)
Net cash provided by financing activities	4,640,238	14,821,895
Change in cash, cash equivalents and restricted cash	(8,254,201)	1,249,699
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4,679	(7,181)
Cash, cash equivalents and restricted cash-beginning of year	22,890,055	21,647,537
Cash, cash equivalents and restricted cash-end of period	14,640,533	22,890,055
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	14,599,347	22,849,885
Restricted cash	41,186	40,170
Total cash, cash equivalents and restricted cash	14,640,533	$ 22,890,055
Non-cash investing and financing activities:
Conversion of Series A convertible preferred stock to common stock	$ 583,702